期刊
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
卷 16, 期 5, 页码 459-463出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejpn.2011.12.012
关键词
Myoclonic-astatic epilepsy; Doose syndrome; Children; Long-term experience; Rufinamide
Introduction: We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). Methods: This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF between July 2007 and June 2010. Clinical information was collected via questionnaire. Responder rate was defined as reduction of seizure frequency >= 50% in comparison to four weeks before starting RUF. Maximum follow-up was eighteen months. Results: Responder rates were 7/8 patients after 3 months, 6/8 patients after 6 months and 5/8 patients after 12 months. RUF seemed particularly effective in the prevention of myoclonic-astatic seizures (comparable with drop attacks in Lennox-Gastaut-Syndrome, for which RUF is particularly effective). Some loss of efficacy was noticed in the longterm observation. Side-effects occurred in two patients. Seizure aggravation was not observed. Conclusion: RUF seems to be a promising therapeutic option in children with MAE. Further studies are warranted to confirm these first observations. (c) 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据